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Abstract
Introduction: Monosodium urate crystals (MSU), the etiological agent of gout, are one of the most potent
proinflammatory stimuli for neutrophils. The modulation of MSU-induced neutrophil activation by inhibitory
receptors remains poorly characterized. The expression of the myeloid inhibitory C-type lectin-like receptor (MICL)
in neutrophils is downregulated by several proinflammatory stimuli, suggestive of a role for this receptor in
neutrophil function. We thus investigated the potential role of MICL in MSU-induced neutrophil activation.
Methods: The expression of MICL was monitored in human neutrophils by flow cytometry and Western blot
analysis after stimulation with MSU. Protein tyrosine phosphorylation was also assessed by Western blot analysis
and the production of IL-1 and IL-8 by enzyme-linked immunosorbent assay. Changes in the concentration of
cytoplasmic free calcium were monitored with the Fura-2-acetoxymethyl ester calcium indicator. MICL expression
was modulated with an anti-MICL antibody in neutrophils and siRNA in the PLB-985 neutrophil-like cell line.
Results: MSU induced the downregulation of MICL expression in neutrophils. A diminution in the expression of
MICL induced by antibody cross-linking or siRNA enhanced the MSU-dependent increase in cytoplasmic calcium
levels, protein tyrosine phosphorylation and IL-8 but not IL-1 production. Pretreatment of neutrophils with
colchicine inhibited the MSU-induced downregulation of MICL expression.
Conclusions: Our findings strongly suggest that MICL acts as an inhibitory receptor in human neutrophils since
the downregulation of MICL expression enhances MSU-induced neutrophil activation. Since MSU downregulates
the expression of MICL, MICL may play a pathogenic role in gout by enhancing neutrophil effector functions. In
support of this notion, colchicine counteracts the MSU-induced loss of MICL expression. Our findings thus also
provide further insight into the potential molecular mechanisms behind the anti-inflammatory properties of this
drug.
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Introduction
Gout is one of the most painful types of arthritis, and its
prevalence is on the rise worldwide [1,2]. The inflamma-
tory reaction typical of an acute gout attack is initiated
by the crystallized form of a by-product of purine meta-
bolism, monosodium urate crystals (MSU). A gout
attack can be viewed in three phases: the initiation
phase, the effector phase and the subsequent resolution
phase. According to the current understanding of the
pathogenesis of acute gout, MSU activate resident
articular cells (for example, macrophages) during the
initiation phase, most commonly in the metatarsopha-
langeal joint [3]. The activation of resident cells by MSU
induces the synthesis of several inflammatory mediators,
including active interleukin 1b (IL-1b), a cytokine that
plays a pivotal role in the pathogenesis of gout, implicat-
ing nucleotide-binding oligomerization domain-like
receptor containing pyrin domain 3 (NLRP3) inflamma-
some in this inflammatory disorder. IL-1b contributes to
the initiation and perpetuation of the effector phase by
virtue of its ability to stimulate endothelial cells of the
vasculature to express potent chemokines (for example,
IL-8) and adhesion molecules responsible for the mas-
sive recruitment of neutrophils to the joint.
The recruitment of a large number of neutrophils to
the affected joint during the effector phase is the patho-
logical hallmark of gouty arthritis [4]. The presence of
activated phagocytes in the joint is one of the main
causes of tissue destruction and pain in gout. When
activated by MSU, neutrophils release a panoply of
inflammatory molecules, including cytokines (for exam-
ple, IL-1b, IL-8, S100) and degradative enzymes, that
perpetuate the inflammatory reaction as well as oxygen
radicals that cause damage to the surrounding tissues
(recently reviewed by Popa-Nita and Naccache [4]). At
the molecular level, the signaling molecules driving
MSU-induced neutrophil responses are just beginning to
be identified. They include activated Src family kinases
(for example, Lyn), Syk, protein kinase C (PKC), phos-
phoinositide 3-kinase (PI3K) and Tec [4]. Since the acti-
vation of Src kinases is an early signaling event, the
majority of MSU-induced effector functions depend on
these kinases.
Animal studies and clinical observations underscore
the pivotal role of the neutrophil in gout. A significant
decrease in MSU-induced inflammation was reported in
neutropenic mice. Moreover, medications used to treat
gout, such as colchicine, downregulate MSU-induced
neutrophil effector functions [4]. It is thus of interest to
characterize molecular mechanisms that regulate MSU-
induced neutrophil activation.
Leukocyte activation is regulated in part by phospha-
tases that block early signaling events of activating
receptors when recruited to the plasma membrane.
Phosphatase recruitment occurs via immunoreceptor
tyrosine-based inhibitory motifs (ITIMs) located in the
cytoplasmic portion of inhibitory receptors expressed on
the surface of leukocytes [5]. Inhibitory receptors can be
classified into two main groups on the basis of their
structure, namely, the immunoglobulin or the C-type
lectin superfamily. Proteins of the latter contain at least
one C-type lectin-like domain (CTLD). Myeloid inhibi-
tory C-type lectin receptors are poorly characterized in
comparison to their counterparts in natural killer cells
(recently reviewed by Pyz et al. [6]). Findings from the
few myeloid inhibitory receptors studied suggest, how-
ever, that these proteins are able to suppress several
phagocyte effector functions, including phagocytosis,
migration and cytokine production [7].
The myeloid inhibitory C-type lectin-like receptor
(MICL) is a type II transmembrane protein comprising
one CTLD in its extracellular domain and an ITIM in its
cytoplasmic domain [8-12]. It is expressed by monocytes,
macrophages, neutrophils, myeloid and plasmacytoid den-
dritic cells. The natural ligands of human MICL remain to
be identified. Although unequivocal evidence of a negative
regulatory function of MICL is still lacking in the pub-
lished literature, the majority of the evidence suggests that
MICL does indeed have inhibitory activity. The recruit-
ment of the SH2-containing tyrosine phosphatases SHP-1
and SHP-2 to the ITIM of MICL was observed in a
macrophage cell line [8]. Moreover, in response to a vari-
ety of Toll-like receptor (TLR) ligands, the cell surface
expression of MICL diminishes in human monocytes and
macrophages, suggestive of a negative regulatory role for
this receptor [9]. In support of this hypothesis, the cell sur-
face expression of MICL was shown to be diminished in
neutrophils recruited to a site of inflammation using an
abrasion model of the skin in human volunteers [9]. The
antibody-induced internalization of MICL in monocyte-
derived dendritic cells, however, showed that the loss of
cell surface MICL can either positively or negatively regu-
late cytokine production. The internalization of MICL
prior to stimulation with lipopolysaccharide (LPS) sup-
presses the production of IL-12p40 and IL-12p70 [10]. In
contrast, the internalization of MICL prior to stimulation
with the CD40 ligand enhances the production of tumor
necrosis factor a (TNF-a), IL-12p40, IL-12p70, IL-6 and
IL-10 [10]. A role for MICL in antibody responses has also
been reported. Targeting antigens to MICL can induce
antibody responses [13].
Since MICL regulates the synthesis of cytokines in den-
dritic cells and its expression is modulated by proinflam-
matory stimuli, the objective of this study was to
investigate the role of MICL in MSU-induced activation
of neutrophils and to determine whether MSU modulate
MICL expression. Herein we report for the first time that
MSU diminish MICL expression in human neutrophils.
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A decrease in MICL expression in neutrophils selectively
enhances MSU-induced cytokine release by neutrophils
and also potentiates early signaling events. We also pro-
vide direct evidence that colchicine inhibits the MSU-
induced loss of cell surface MICL, suggesting that the
regulation of MICL expression may be a new mechanism
through which this drug dampens inflammation.
Methods
Antibodies and chemicals
Two different antibodies against MICL were used in this
study. Monoclonal antibodies 50C1 [13] and HB3 which
was kindly provided by Dr G Brown [8] recognize extra-
cellular epitopes of MICL. FITC-conjugated F(ab’)2 frag-
ment goat anti-mouse IgG antibody (Fc fragment-specific,
catalog no. 115-096-071) was purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA, USA).
Horseradish peroxidase-labeled sheep anti-mouse immu-
noglobulins (IgGs) (no. NXA931) were obtained from GE
Healthcare (Uppsala, Sweden). The antiphosphotyrosine
(clone 4G10, no. 05-321) and the anti-p85 (no. 06-195)
antibodies were purchased from Upstate Biotechnology
(Lake Placid, NY, USA). Monoclonal anti-flotillin-1 anti-
body (no. 610820) was purchased from BD Transduction
Laboratories (Mississauga, ON, Canada). The mouse
IgG2a isotype antibody (no. 0572) was purchased from
Beckman Coulter (Mississauga, ON, Canada). Anti-CD11b
antibody (OKM1, no. 88012702) was purchased from
Sigma-Aldrich Canada (Oakville, ON, Canada), and
the anti-FPRL1 antibody was obtained from R&D Systems
(Minneapolis, MN, USA). Sodium orthovanadate
(Na3VO4), N
6,2′-O-dibutyryladenosine 3′,5′-cyclic mono-
phosphate sodium salt (dibutyryl cyclic adenosine mono-
phosphate (dibutyryl cAMP)), colchicine and Dextran
T500 were obtained from Sigma-Aldrich Canada. 3-[(3-
Cholamidopropyl)dimethylammonio]propanesulfonic acid
(CHAPS), aprotinin and leupeptin were purchased from
Roche Applied Science (Laval, QC, Canada). The Western
Lightning Chemiluminescence Plus ECL kit was obtained
from PerkinElmer (Boston, MA, USA). Ficoll-Paque and
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) were obtained from Wisent (St-Bruno, QC,
Canada). Protein A Sepharose was purchased from GE
Healthcare. Gelatin was obtained from Fisher Scientific
(Nepean, ON, Canada). Fura-2-acetoxymethyl ester (Fura-
2AM) was obtained from Invitrogen (Burlington, ON,
Canada), and the triclinic MSU crystals were synthesized
and characterized as previously described by Naccache et
al. [14]. Endotoxin contamination was ruled out by Limu-
lus amebocyte lysate assay. siGENOME SMARTpool
MICL (no. D-021369-01) and siGENOME nontargeting
small interfering RNA (siRNA) pool 1 (negative control,
no. D-001206-13-05) were purchased from Dharmacon
Inc (Lafayette, CO, USA).
Cells
The Institutional Review Board of Laval University (Que-
bec, QC, Canada) approved the study, and volunteers
signed a consent form. Neutrophils were collected from
healthy adult volunteers and isolated as previously
described [15]. They were resuspended in Mg2+-free
Hanks’ balanced salt solution (HBSS) containing 1.6 mM
CaCl2. The myeloid cell line PLB-985 was obtained from
the German Collection of Microorganisms and Cell Cul-
tures (DSMZ; Braunschweig, Germany) and grown in
RPMI 1640 medium containing 10% decomplemented
fetal bovine serum (FBS), 10 mM HEPES, 1 mM Na+ pyr-
uvate at 37°C in a 5% CO2 humidified atmosphere. The
cells were maintained in culture for 12 passages before
new batches were thawed. To induce differentiation to a
neutrophil-like phenotype, PLB-985 cells were cultured in
medium supplemented with 0.3 mM dibutyryl cAMP for
3 days prior to each experiment.
Transfection of dibutyryl cAMP-differentiated PLB-985
cells
One day following the initiation of differentiation with
0.3 mM dibutyryl cAMP, PLB-985 cells were transiently
transfected using a nucleofection system obtained from
Amaxa Biosystems (Cologne, Germany). Briefly, 2 × 106
cells were centrifuged and resuspended in 100 µl of
nucleofection buffer (25 mM HEPES, pH 7.4, 120 mM
KCl, 2 mM MgCl2, 10 mM K2HPO4, 5 mM L-cysteine)
containing 3 µg of MICL-specific siRNA (siMICL) or
negative control siRNA (siCtrl). The samples were trans-
ferred into an electroporation cuvette, and transfections
were performed using the program setting U-002. After
nucleofection, cells were immediately transferred into
prewarmed RPMI 1640 complete medium containing
0.3 mM dibutyryl cAMP, 10% FBS, 10 mM HEPES,
1 mM Na+ pyruvate and maintained at 37°C in a 5%
CO2 humidified atmosphere. Two days after nucleofec-
tion, cells were harvested and resuspended in Mg2+-free
HBSS containing 1.6 mM CaCl2 for analysis.
Flow cytometry analysis
To monitor the plasma membrane expression of MICL on
neutrophils stimulated with different agonists, neutrophils
were transferred into tubes cooled in an ice bath to termi-
nate the stimulations, then centrifuged at 400 × g for
2 min at 4°C. The cell pellets were then resuspended in
buffer with 50C1 (1 µg/ml) or the IgG2a isotype control
antibody and incubated for 30 min on ice, washed, and
centrifuged, and the resuspended cell pellets were incu-
bated for a further 30 min on ice with FITC-labeled goat
antimouse Fcg-specific IgG (diluted 1:100 in HBSS/bovine
serum albumin (HBSS/BSA) solution). Cells were then
washed twice in HBSS/BSA and analyzed by flow cytome-
try using a FACSCanto II flow cytometer obtained from
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BD Biosciences (San Jose, CA, USA). To monitor the anti-
body-induced internalization of cell surface MICL, freshly
isolated neutrophils were incubated with 50C1 antibody
(1 µg/ml) or IgG2a isotype antibodies for the indicated
times at 37°C and then washed, and the resuspended cell
pellets were incubated for a further 30 min on ice with
FITC-labeled goat antimouse Fcg-specific IgG (diluted
1:100 in HBSS/BSA solution). In some experiments, neu-
trophils were treated with 10 µM colchicine or diluent
(dimethyl sulfoxide (DMSO)) for 30 min at 37°C and cen-
trifuged to wash away the drug prior to stimulation with
1 mg/ml MSU for 20 min at 37°C.
Trichloroacetic acid protein precipitation
Human neutrophils (20 × 106 cells/ml) were stimulated
with MSU crystals (1 µg/ml) at 37°C and quickly centri-
fuged, then supernatants were precipitated with 15% tri-
chloroacetic acid for 30 min at 4°C. Samples were then
centrifuged at 16,000 × g for 5 min and washed three
times with acetone. Pellets were dried at 95°C for 2 min
and resuspended in modified Laemmli buffer.
Enzyme-linked immunosorbent assay
The assessment of the extracellular IL-8 was performed
using commercially available enzyme-linked immunosor-
bent assay (ELISA) kits (human IL-8 cytoset, no.
CHC1303) from Invitrogen. All samples were measured
in duplicate. Briefly, dibutyryl cAMP-differentiated PLB-
985 cells were stimulated for 3 h at 37°C with 1 mg/ml
MSU crystals in RPMI 1640 and centrifuged (16,000 × g
for 5 min), then the supernatants were harvested and fil-
tered. Extracellular IL-8 was quantified using commer-
cially available ELISA kits (BD Biosciences). All samples
were measured in triplicate. For the quantitation of
extracellular IL-1b, neutrophils primed with TNF-a or
incubated in buffer were stimulated for 8 h with MSU
at 37°C, and IL-1b was quantified in the cell-free super-
natant using a commercially available ELISA kit
obtained from eBioscience (catalog no. 88-7010-22; San
Diego, CA, USA). All samples were measured in dupli-
cate. To determine the effect of colchicine on the MSU-
induced production of IL-8, neutrophils were treated
with 10 µM colchicine or diluent (DMSO) for 30 min at
37°C prior to adding MSU (1 mg/ml) or buffer to the
neutrophil-colchicine mixture and incubating it for a
further 3 h at 37°C. It is of note that the effect of colchi-
cine on neutrophils is reversible (data not shown). For
colchicine to be effective, it should not be removed
from the neutrophil suspension for the duration of the
experiment for assays longer than 20 min.
Electrophoresis and immunoblotting
For Western blot analysis, cell suspensions were trans-
ferred directly into the same volume of 2× boiling
modified Laemmli sample buffer (1× buffer: 62.5 mM
Tris·HCl (pH 6.8), 4% (wt/vol) sodium dodecyl sulfate
(SDS), 5% (vol/vol) b-mercaptoethanol, 8.5% (vol/vol)
glycerol, 2.5 mM orthovanadate, 10 μg/ml leupeptin,
10 μg/ml aprotinin and 0.025% bromophenol blue) to
terminate cell activation with MSU, then boiled for
7 min. Proteins were separated by SDS-PAGE on 10%
acrylamide gels under nonreducing conditions and
transferred to polyvinylidene fluoride (PVDF) mem-
branes. Blocking agents and antibodies were diluted in a
Tris-buffered saline Tween 20 (TBST) solution (25 mM
Tris·HCl, pH 7.8, 190 mM NaCl, 0.15% vol/vol Tween
20). PVDF membranes were incubated in blocking solu-
tion (5% wt/vol dried milk in TBST) prior to immuno-
blotting with the anti-MICL antibody (HB3 antibody) or
anti-flotillin-1 antibody. Gelatin solution (2% wt/vol)
was used as a blocking solution prior to immunoblotting
with the antiphosphotyrosine (4G10) antibody. Anti-
MICL and anti-flotillin antibodies were diluted 1:1,000
and antiphosphotyrosine antibodies was diluted 1:2,000.
Horseradish peroxidase-labeled sheep antimouse IgG
was diluted 1:20,000 in TBST solution. Chemilumines-
cence reagents were used to detect antibodies with a
maximal exposure time of 5 min. All the immunoblots
presented were controlled for equal protein loading with
an anti-p85 of PI3K antibody.
Calcium mobilization
Neutrophils (1 × 107 cells/ml) were incubated for 30 min
at 37°C with 1 μM Fura-2AM, washed once in HBSS,
resuspended to a concentration of 5 × 106 cells/ml and
transferred to a temperature-controlled (37°C) cuvette
compartment of a spectrofluorometer (SLM 8000; SLM
Instruments, Urbana, IL, USA). Cell-associated fluores-
cence was monitored at an excitation wavelength of
340 nm and an emission wavelength of 510 nm. The inter-
nal calcium concentrations were calculated as described by
Grynkiewicz et al. [16].
Statistical analysis
Statistical analyses were performed using a two-tailed
Student’s paired t-test on the raw data with GraphPad
Prism 4 software (GraphPad Software, La Jolla, CA,
USA). Significance was considered to be attained at a
value of P < 0.05.
Results
Monosodium urate crystals reduce myeloid inhibitory
C-type lectin-like receptor expression in human neutrophils
The modulation of the cell surface expression of MICL by
a variety of TLR agonists in human monocytes, macro-
phages and monocyte-derived dendritic cells, as well as
mouse neutrophils, prompted us to determine whether
MICL expression is downregulated by proinflammatory
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stimuli, in this case, MSU. The cell surface expression of
MICL was monitored by flow cytometry in human neutro-
phils stimulated for up to 20 min with 1 mg/ml MSU
(Figure 1A). After 1 min of stimulation, the level of
expression of cell surface MICL remained unchanged. In
contrast, a significant reduction in the expression of MICL
was observed after 20 min of stimulation with MSU. For
comparative purposes, the modulation of the cell surface
expression of MICL by soluble agonists was also exam-
ined. None of the agonists tested, TNF-a, granulocyte-
macrophage colony-stimulating factor, granulocyte col-
ony-stimulating factor, platelet-activating factor, the TLR4
ligand LPS and the TLR1 and TLR2 ligand Pam3CSK4
(N-palmitoyl-S-(2,3-bis(palmitoyloxy)-(2RS)-propyl)-(R)-
Cys-(S)-Ser-(S)-Lys4 trihydrochloride
data not shown), modulated MICL plasma membrane
expression. Similarly, we detected no change in the sur-
face expression of MICL in response to the particulate
stimulus, nonopsonized zymosan (Figure 1B). MSU is
thus the only stimulus tested that can directly induce
the internalization of cell surface MICL. To determine
whether the internalization of MICL observed with the
above stimuli could be induced with the anti-MICL
antibody (clone 50C1), neutrophils were incubated with
50C1 antibody, and internalization was assessed by flow
cytometry with a fluorochrome-conjugated secondary
antibody as described in the Methods section. We show
that 50C1 can induce the internalization of cell surface
MICL in human neutrophils (Figure 1C).
We then asked whether the change in cell surface MICL
was accompanied by the degradation of the receptor. To
test this hypothesis, an aliquot of the human neutrophil
suspension (cell pellet and supernatant) stimulated with
MSU was lysed and assessed by Western blot analysis with
an anti-MICL antibody. A significant decrease in the
amount of total MICL was observed (Figures 2A and 2B).
Since the lysate analyzed represents extracellular and
intracellular MICL, these results indicate that the fate of
Figure 1 Surface myeloid inhibitory C-type lectin-like receptor (MICL) expression is significantly decreased upon activation of human
neutrophils with monosodium urate crystals (MSU). The plasma membrane expression of MICL was examined by flow cytometry on freshly
isolated neutrophils (10 × 106 cells/ml) after incubation at 37°C with (A) MSU (1 mg/ml) for 20 min, (B) nonopsonized zymosan (z) (ratio = 10
z/cell), lipopolysaccharide (LPS) (22.5 ng/ml in 1× Hanks’ balanced salt solution containing 5% decomplemented fetal bovine serum), tumor
necrosis factor a (TNF-a; 100 U/ml), granulocyte-macrophage colony-stimulating factor (80 nM), granulocyte colony-stimulating factor (50 ng/ml)
or platelet-activating factor (10−6 M) for 15 min or (C) the 50C1 antibody (1 µg/ml) or IgG2a isotype control antibody for 5 min or 20 min as
described in Methods. MICL expression was compared to the control. The raw flow cytometry data in (A) is shown in the right panel. These
graphs are compilations from four independent experiments.
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the MICL receptor after its internalization is its degrada-
tion. Analysis of the cell pellet and supernatant separately
supported this interpretation of our observations because
MICL was not detectable in the supernatant of MSU-acti-
vated neutrophils (Figure 2C). Stimulation of neutrophils
with MSU thus induces not only the downregulation of the
expression of cell surface MICL but also its degradation.
Myeloid inhibitory C-type lectin-like receptor negatively
regulates the production of IL-8 by monosodium urate
crystal-activated human neutrophils
To determine the functional significance of the downre-
gulation of MICL expression by MSU, we next exam-
ined the effect of the silencing of MICL expression on
MSU-induced cytokine production because MICL is
Figure 2 Total MICL expression is reduced upon activation of human neutrophils with MSU. (A) Freshly isolated human neutrophils (20 × 106
cells/ml) were incubated with MSU (1 mg/ml) at 37°C, then the stimulation was terminated. Aliquots of the suspension were stopped at 20 min by
transferring it directly into the same volume of nonreducing 2× boiling modified Laemmli sample buffer. Whole-cell lysates were probed by Western
blotting for MICL (anti-MICL clone HB3; upper panel) and phosphoinositide 3-kinase (PI3K)-p85 (lower panel) as loading control. This result is
representative of eight independent experiments. (B) Densitometric ratios from (A) are represented on the graph. (C) Human neutrophils (20 × 106 cells/
ml) were incubated with MSU (1 mg/ml) at 37°C. Aliquots of the suspension were centrifuged, and pellets were stopped at the indicated times in
nonreducing 2× boiling modified Laemmli sample buffer. The supernatants were precipitated with 2,2,2-trichloroacetic acid as described in Methods.
Pellets and supernatants were probed by Western blotting for MICL (anti-MICL clone HB3). This result is representative of three independent experiments.
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known to modulate the synthesis of cytokines by mono-
cyte-derived dendritic cells. The refractory nature of
neutrophils to transfection prompted us to use PLB-985
cells that acquire a neutrophil-like phenotype upon dif-
ferentiation with dibutyryl cAMP [17-19]. Upon differ-
entiation, PLB-985 cells increase the cell surface
expression of Mac-1 (Figure 3A and [20]) and FLPR1
(Figure 3A). Moreover, both published results and our
unpublished observations reveal that the response of
this cell line to MSU crystals is similar to that of human
neutrophils [19].
To verify that the expression of MICL can be knocked
down in PLB-985 cells, the cells were transfected with
control siRNA or MICL siRNA, and the cell surface
expression of MICL was determined by flow cytometry.
MICL siRNA significantly diminishes the cell surface
Figure 3 MICL modulates MSU-induced IL-8 secretion in human neutrophils. The PLB-985 cell line was differentiated with dibutyryl cyclic
adenosine monophosphate (dibutyryl cAMP) for 72 h as described in Methods. The plasma membrane expression of Mac-1 (OKM1), the formyl
peptide receptor-like 1 (FPRL1) and MICL were analyzed by flow cytometry on differentiated and undifferentiated PLB-985 cells. Immunoglobulin
G2b (IgG2b) and IgG2a were used as control isotypes. (B) Dibutyryl cAMP-differentiated, neutrophil-like PLB-985 (20 × 106 cells/ml) were
transfected using a nucleofection system with a MICL-specific small interfering RNA (siMICL) or with a negative control small interfering RNA
(siCtrl). Cells were then stimulated for 3 h at 37°C with 1 mg/ml MSU in RPMI 1640 medium. Cells were centrifuged (16,000 × g for 5 min), and
the supernatants were harvested and filtered. Extracellular interleukin 8 (IL-8) was quantitated using commercially available enzyme-linked
immunosorbent assay (ELISA) kits. All samples were measured in duplicate. This graph is a compilation of four independent experiments. (C)
MICL surface expression was monitored by flow cytometry following siRNA transfections. Cells (10 × 106 cells/ml) were incubated with 50C1
antibody (2 µg/ml) for 30 min on ice, washed and incubated with fluorescein isothiocyanate (FITC)-labeled goat antimouse Fcg-specific IgG
(diluted 1:100 in Hanks’ balanced salt solution/bovine serum albumin (HBSS/BSA)) for 30 min on ice. Cells were then washed twice in HBSS/BSA
and analyzed by flow cytometry using a BD FACSCanto II flow cytometer obtained from BD Biosciences. This graph is a compilation of four
independent experiments. (D) Human neutrophils (20 × 106 cells/ml) were incubated with anti-MICL antibody (clone 50C1, 2 μg/ml) or IgG2a
isotype for 5 min at 37ºC and then washed. Cells were then stimulated with MSU at 1 mg/ml or not for 3 h at 37°C. Extracellular IL-8 was
monitored as described in (B). All samples were measured in triplicate. This result is a compilation of five independent experiments.
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expression of MICL (P = 0.021) (Figure 3B). Moreover,
the silencing of MICL expression has no effect on the
differentiation of PLB-985 cells. The level of expression
of Mac-1 and FLPR1 is the same in differentiated cells
transfected with the control or MICL siRNA (data not
shown).
Having demonstrated that MICL expression can be
silenced by MICL-specific siRNA in neutrophil-like PLB-
985 cells, we next examined how the diminution in
MICL expression affects MSU-induced IL-8 production.
The amount of IL-8 measured in the cell-free superna-
tant of MSU-activated, dibutyryl cAMP-differentiated
PLB-985 silenced for MICL expression was significantly
superior in comparison to cells transfected with control
siRNA (Figure 3C). To confirm this observation in
human neutrophils, the internalization of cell surface
MICL was induced with the 50C1 antibody prior to sti-
mulation with MSU, as shown in Figure 1C. Neutrophils
incubated with 50C1 prior to stimulation with MSU pro-
duced significantly larger amounts of IL-8 in the cell-free
supernatant (Figure 3D) than in those treated with an
isotype antibody (IgG2a). Thus, using two different
experimental strategies, we have produced evidence that
a reduction in the cell surface expression of MICL
potentiates MSU-induced IL-8 production in neutrophils.
Production of IL-1 by monosodium urate crystal-activated
human neutrophils is not regulated by myeloid inhibitory
C-type lectin-like receptor
Having demonstrated the modulation of the MSU-
induced release of IL-8 by human neutrophils, we next
examined the possibility that MICL may regulate the pro-
duction of IL-1b, since this cytokine is reported to play a
pivotal role in gout. The MSU-induced synthesis of IL-1b
by macrophages, cells that produce this cytokine during
the initiation phase of gout, is well-documented. In con-
trast, the production of IL-1b by MSU-stimulated neu-
trophils remains poorly characterized. We thus examined
the ability of neutrophils to synthesize and release IL-1b
in response to MSU. As shown in Figure 4, neutrophils
stimulated with MSU do not release detectable amounts
of IL-1b. This may be explained by the fact that the
synthesis of this cytokine is a multistep process involving
the synthesis of pro-IL-1b and its subsequent inflamma-
some-mediated maturation. IL-1b synthesis requires two
signals. The first signal is thought to modulate the
threshold of the inflammasome and the second, to acti-
vate the inflammasome-dependent maturation of pro-IL-
1b Indeed, the stimulation of neutrophils with MSU after
TNF-a priming induces the release of a significant
amount of IL-1b in the cell-free supernatant. A similar
Figure 4 MICL does not modulate MSU-induced IL-1b production in primed, human neutrophils. Resting human neutrophils (20 × 106
cells/ml) or neutrophils incubated with the IgG2a isotype antibody, 50C1, in the presence or absence of TNF-a were stimulated with MSU (1
mg/ml) for 8 h at 37°C and centrifuged, and IL-1b was quantified in the cell-free supernatant by ELISA as described in Methods. All samples
were measured in duplicate. This graph is a compilation of four independent experiments.
Gagné et al. Arthritis Research & Therapy 2013, 15:R73
http://arthritis-research.com/content/15/4/R73
Page 8 of 15
amount of IL-1b was measured in the cell-free superna-
tant of TNF-a-primed neutrophils stimulated with MSU
after the 50C1-induced internalization of MICL.
Together, the above observations indicate that MICL
does not regulate the production of IL-1b in neutrophils
stimulated with MSU.
Diminution of myeloid inhibitory C-type lectin-like
receptor expression enhances monosodium urate crystal-
induced signaling in human neutrophils
Having observed a modulation of IL-8 production by
MICL, we next asked whether MICL modulates signaling
pathways activated by MSU. We chose to focus on the
modulation of MSU-induced tyrosine phosphorylation of
intracellular proteins, since ITIM-bearing receptors are
notable for regulating early signaling events. Tyrosine
phosphorylation of intracellular substrates was visualized
by Western blot analysis using an antiphopshotyrosine
antibody. The series of bands shown in the blot in Figure 5
represent the distinct tyrosine phosphorylation profile
induced in neutrophils by MSU and is consistent with that
previously described [21]. A rapid and transient increase in
the tyrosine phosphorylation of intracellular substrates was
observed within 1 min after stimulation of neutrophils with
MSU (Figure 5). Maximum tyrosine phosphorylation was
observed approximately 1 to 2 min following MSU stimu-
lation and began to diminish by 5 min. Even though a simi-
lar kinetics in the tyrosine phosphorylation of intracellular
substrates was observed in neutrophils stimulated with
MSU after 50C1 engagement, the intensity of the tyrosine
phosphorylation profile was much higher in these cells
than that in neutrophils stimulated with MSU alone. As a
control, we show that 50C1 alone does not induce an
intense tyrosine phosphorylation profile of intracellular
substrates.
Another early signaling event is the increase in the
intracellular levels of cytoplasmic free calcium. We pro-
vide evidence that the 50C1-induced diminution of the
expression of cell surface MICL significantly enhanced
the MSU-induced increase in cytoplasmic free calcium
(Figure 6).
Together, the above findings are suggestive of a nega-
tive regulatory role for MICL because a decrease in its
cell surface expression enhances two of the earliest
Figure 5 MICL modulates the MSU-induced tyrosine phosphorylation pattern in human neutrophils. Human neutrophils (20 × 106 cells/
ml) were preincubated with anti-MICL antibody (clone 50C1, 2 μg/ml) (+) or IgG2a isotype (-) for 5 min and then washed. Next, cells were
stimulated with MSU (1 mg/ml) at 37°C. Aliquots of the cell suspension were stopped at the indicated times by transferring them directly into
the same volume of 2× boiling modified Laemmli sample buffer. Whole-cell lysates were probed by Western blotting for tyrosine
phosphorylation (clone 4G10, upper panel) and flotillin-1 (lower panel), the loading control. This result is representative of three independent
experiments.
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Figure 6 MICL modulates MSU-induced calcium mobilization in human neutrophils. (A) Human neutrophils (10 × 106 cells/ml) were
preincubated with Fura-2AM (1 µM) for 30 min at 37°C. The extracellular probe was removed by washing in HBSS, and the cells were
resuspended at 5 × 106 cells/ml. Anti-MICL antibody (clone 50C1, 2 μg/ml) or IgG2a isotype was added for 5 min. Cells were transferred to a
thermostat-controlled (37°C) cuvette compartment of an SLM 8000 spectrofluorometer. Calcium mobilization was measured following the
addition of 1 mg/ml MSU at 37°C. Fluorescence was monitored at an excitation wavelength of 340 nm and an emission wavelength of 510 nm.
The internal calcium concentrations were calculated as described by Grynkiewicz et al. [16]. This result is representative of four independent
experiments.
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signaling events in neutrophils upon stimulation with
MSU, the tyrosine phosphorylation of intracellular pro-
teins and an increase in intracellular levels of cytoplas-
mic free calcium.
Colchicine reduces the internalization of myeloid
inhibitory C-type lectin-like receptor on human
neutrophils
The modulation by MICL of various neutrophil responses
toward MSU led us to hypothesize that anti-inflammatory
drugs may dampen inflammation by targeting MICL. Our
working hypothesis is that MICL negatively regulates
MSU-induced neutrophil responses, since a decrease in its
expression enhances the effector functions of neutrophils
toward MSU. Because colchicine is very effective in inhi-
biting a variety of MSU-induced neutrophil effector func-
tions, some of which are modulated by MICL, including
calcium mobilization and tyrosine phosphorylation, the
effect of this anti-inflammatory drug on the MSU-induced
internalization of MICL was examined. The addition of
colchicine to resting neutrophils did not affect the expres-
sion of MICL as determined by flow cytometry. In con-
trast, the MSU-induced internalization of MICL was
significantly retarded in neutrophils pretreated with col-
chicine (Figure 7). This effect of colchicine on MICL inter-
nalization is specific for the MSU-induced internalization
of MICL because colchicine was not able to retard the
50C1-induced loss of MICL cell surface expression.
Together, these observations strongly suggest that the
anti-inflammatory properties of colchicine may be partially
explained by the ability of this drug to preserve the expres-
sion of MICL on the surface of human neutrophils.
Colchicine inhibits the production of IL-8 by monosodium
urate crystal-activated human neutrophils
Colchicine is known to inhibit all the MSU-induced neu-
trophil responses modulated by MICL. The effect of the
alkaloid on the production of IL-8 has not been examined
yet, however. Its effect on the production of this cytokine
in response to MSU was thus determined. Neutrophils
incubated with colchicine produced significantly lower
amounts of IL-8 when activated with MSU than neutro-
phils stimulated with MSU in the absence of the drug
(Figure 8). This finding supports the notion that colchicine
inhibits IL-8 production by neutrophils stimulated with
MSU in part through MICL because colchicine favors the
retention of this inhibitory receptor on the cell surface,
precluding the full activation of the neutrophil.
Discussion
Inhibitory receptors are essential for the maintenance of
immune homeostasis by abrogating signaling pathways
that lead to cellular activation [5]. Even though inhibi-
tory receptors may contribute to the pathogenesis of
inflammatory diseases by virtue of their ability to modu-
late leukocyte activation, little is known about their
roles in disease. This is the first report of the modula-
tion of the expression of an inhibitory receptor by the
etiological agent of gout. The activation of human neu-
trophils with MSU results in the loss of MICL expression.
The functional significance of the diminution of MICL
expression is an enhancement in the MSU-induced
release of IL-8. This finding is of clinical relevance
because IL-8 is a potent neutrophil chemoattractant. The
loss of MICL expression may thus be a requisite for the
recruitment and/or perpetuation of neutrophil-driven
gout flares. Moreover, we also show that an inflammatory
drug used to treat gout, colchicine, inhibits the effect of
MSU on MICL expression.
Our observation that MSU downregulates MICL expres-
sion adds to a growing list of proinflammatory stimuli that
diminish the cell surface expression of MICL in neutro-
phils. MSU is the first damage-associated molecular pat-
tern demonstrated to modulate MICL expression. The
biological significance of the negative modulation of MICL
expression in neutrophils by proinflammatory stimuli
other than MSU (mostly TLR agonists) remains largely
unexplored, rendering the interpretation of these results
challenging. One report has investigated the functional
effect of the diminution of cell surface MICL on cytokine
synthesis in monocyte-derived dendritic cells [10]. In that
report, Chen et al. demonstrated that a diminution in the
expression of cell surface MICL inhibited or augmented
cytokine production in a stimulus-dependent manner. In
response to LPS, the production of TNF-a, IL-12p40 and
IL-12p70 was suppressed upon MICL internalization. In
contrast, the production of TNF-a, IL-12p40, IL-12p70,
IL-6 and IL-10 was enhanced in response to CD40 ligand.
Since inhibitory receptors can dampen cellular activation
or, in some cases, activate the cells, it remains unclear
whether MICL is an inhibitory receptor. We used a siRNA
approach to resolve this issue. Our demonstration that the
silencing of MICL expression significantly enhances the
release of IL-8 by MSU-activated neutrophils strongly sup-
ports the notion that MICL acts as an inhibitory receptor
in human neutrophils.
The modulation of IL-8 production by MICL in neutro-
phils is of relevance to gout. The massive recruitment of
neutrophils to the inflamed joint is a pathological hallmark
of gout, and this recruitment is reduced in mice deficient
in chemokine (C-X-C motif) receptor 2 (CXCR2). It is thus
reasonable to propose that the MSU-induced downregula-
tion of MICL expression releases the inhibitory activity of
this receptor in neutrophils permitting the activation of the
neutrophil by this nonmicrobial agent. Interestingly, MICL
does not regulate the MSU-induced production of IL-1b.
The molecular mechanisms underlying the selective nature
of MICL regulation of the production of cytokines by
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MSU-activated neutrophils remain to be identified.
Whether MICL modulates the release of other chemotactic
factors or cytokines by neutrophils remains to be deter-
mined. With regards to the ability of MICL to modulate
additional MSU-induced neutrophil responses, we did not
observe any modulation of MSU-induced degranulation or
5-lipoxygenase production in human neutrophils subse-
quent to the antibody-induced internalization of MICL
Figure 7 Colchicine inhibits the MSU-induced internalization of MICL in human neutrophils. Freshly isolated human neutrophils were treated
with colchicine (10 µM) (+) or dimethyl sulfoxide (DMSO) (-) for 30 min at 37°C and then incubated with (A) MSU (1 mg/ml) for 20 min at 37°C or (B)
50C1 for 5 min at 37°C. The stimulations were terminated by transferring the tubes to an ice bath, followed by centrifugation at 400 × g for 2 min at 4°
C. The cell pellets were washed in cold HBSS containing 0.005% BSA and incubated with (A) 50C1 for 30 min, followed by incubation with FITC-
labeled goat antimouse Fcg-specific IgG (diluted 1:100 in HBSS/BSA) for 30 min on ice, or (B) FITC-labeled goat anti-mouse Fcg-specific IgG (diluted
1:100 in HBSS/BSA) for 30 min on ice. Cells were then washed twice in HBSS/BSA and analyzed by flow cytometry using the FACSCanto II flow
cytometer (BD Biosciences). This graph is a compilation of 7 independent experiments in (A) and 3 independent experiments in (B).
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(data not shown). These observations suggest that MICL
modulates a subset of molecular pathways employed by
MSU to activate human neutrophils.
At the molecular level, we show that MICL modulates
early MSU-induced signaling events in neutrophils. The
stimulation of neutrophils with MSU induced the loss of
cell surface MICL leading to the enhancement of the
MSU-induced increase in the concentration of intracellu-
lar calcium and tyrosine phosphorylation of intracellular
substrates. These observations corroborate the observed
enhancement in MSU-induced IL-8 production upon the
downregulation of MICL expression. Both MSU-induced
tyrosine phosphorylation and IL-8 production depend on
the activation of Src kinases in neutrophils. The inhibi-
tion by MICL of MSU-induced early signaling events is
consistent with the known mode of action of inhibitory
receptors and is strongly suggestive that MICL may regu-
late several MSU-induced neutrophil effector functions
driven by downstream signaling events.
Neutrophils pretreated with colchicine internalize sig-
nificantly less cell surface MICL in the presence of
MSU. This observation provides additional evidence for
the ability of MICL to negatively regulate the MSU-
induced activation of neutrophils. We propose that
colchicine preserves the cell surface expression and con-
sequently the inhibitory activity of MICL, shifting the
balance between pro- and anti-inflammatory signals
toward the latter. It thus follows that MSU may induce
tyrosine phosphorylation of intracellular substrates and
the mobilization of intracellular calcium in part by
internalizing MICL, because these neutrophil responses
are enhanced subsequent to the antibody-induced inter-
nalization of MICL and inhibited by colchicine. Regard-
ing the MSU-induced secretion of IL-8, the ability of
colchicine to inhibit this neutrophil response to MSU
remains unexplored. We thus investigated the effect of
colchicine on the production of this cytokine in
response to MSU. Colchicine downregulates the MSU-
induced release of IL-8 in human neutrophils (Figure 8).
Together, these observations strongly suggest that MICL
regulates very early signaling events involving Src
kinases because MSU-induced tyrosine phosphorylation
of intracellular substrates, as well as the increases in the
concentrations of free cytosolic calcium and the produc-
tion of IL-8, are all Src tyrosine kinase-dependent
events. MICL is the first inhibitory pathway identified
that could partly explain the antiphlogistic activity of
colchicine. Since colchicine destabilizes microtubules by
binding a and b monomers of tubulin, it is not unrea-
sonable to suggest that MICL interacts directly or indir-
ectly with the microtubule network.
A limitation of our experimental approach is that the
internalization of MICL was induced prior to MSU sti-
mulation to investigate the effect of MICL on MSU-
induced responses. Although this approach is widely
used to investigate inhibitory receptors whose ligands
remain unidentified, it remains to be determined
whether cells expressing a mutant form of MICL that is
resistant to MSU-induced internalization and/or degra-
dation respond more weakly to MSU.
Figure 8 Colchicine modulates MSU-induced IL-8 secretion in human neutrophils. Neutrophils were incubated in colchicine (10 µM) (+) or
DMSO (-) for 30 min at 37°C prior to adding MSU (1 mg/ml) or buffer to the neutrophil-colchicine mixture and incubating it for a further 3 h at 37°C.
The quantity of IL-8 in the supernatant was determined by ELISA. A compilation of the data from three independent experiments is shown (n = 3).
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As mentioned above, MSU are the first damage-
associated molecular pattern shown to modulate MICL
expression and consequentially its function. The regulation
of MICL expression by damage-associated molecular pat-
terns may differ from that of pathogen-associated molecu-
lar patterns and other proinflammatory stimuli. Indeed,
MSU is the only stimulus that we studied that modulates
MICL expression in resting neutrophils. Moreover, studies
that previously published the diminution of cell surface
MICL by stimuli other than damage-associated molecular
patterns were performed on primed neutrophils. We show
that in resting neutrophils, however, MICL expression is
not modulated by proinflammatory stimuli that are not
damage-associated molecular patterns. Together, these
observations indicate that neutrophils have to receive two
stimuli and/or signals prior to mobilizing cell-surface
MICL when activated with non-damage-associated molecu-
lar pattern stimuli. In contrast, damage-associated molecu-
lar patterns seem to be able to override the necessity of a
primary signal (neutrophil priming) and affect MICL
expression directly.
Conclusion
Our findings strongly suggest that MICL may play a
pathogenic role in gout by being one of the targets of
MSU. We propose that MSU downregulate the inhibitory
activity of MICL by diminishing its expression, resulting in
the full activation of human neutrophils. In contrast, col-
chicine has the opposite effect on the cell surface expres-
sion of MICL. MICL is thus a potential therapeutic target
for gout. Further characterization of the role of MICL in
MSU-induced neutrophil activation and the molecular
events driving MICL function is necessary to shed light on
the pathogenic role of MICL in gout and its potential as a
drug target. Since neutrophils are the principal players in
the inflammatory flares typical of gout, it is not unreason-
able to suggest that MICL may also play a similar patho-
genic role in other chronic diseases characterized by
recurrent, neutrophil-driven inflammatory episodes, such
as rheumatoid arthritis. It is thus of interest to gain further
insight into the potential role of MICL in the effector
phase of these chronic inflammatory diseases.
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